Using machine learning to find new treatment targets for Alzheimer's disease
Interpretable Machine Learning to Identify Alzheimer's Disease Therapeutic Targets
['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-10613437
This study is looking at how our genes might play a role in the buildup of harmful proteins in Alzheimer's disease, and it's for anyone interested in finding better ways to spot these proteins and improve treatment options.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10613437 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the genetic factors that contribute to the formation of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. By analyzing gene expression data from human brain tissues, the researchers aim to identify biomarkers that can predict the presence of these harmful proteins. They are employing advanced machine learning techniques to create interpretable models that can improve the accuracy of biomarker discovery, potentially leading to better therapeutic targets. The goal is to overcome the limitations of current biomarker approaches, which often yield false positives and low clinical success rates.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Alzheimer's disease or those at risk for developing it.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease by identifying reliable therapeutic targets.
How similar studies have performed: Previous research has shown promise in using machine learning for biomarker discovery, but this approach aims to significantly improve upon existing methods.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LEE, SU-IN — UNIVERSITY OF WASHINGTON
- Study coordinator: LEE, SU-IN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease